share_log

Arcutis Biotherapeutics | 8-K: Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics | 8-K: Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics | 8-K：Arcutis公布2024年第二季度财务业绩并提供业务最新情况
美股SEC公告 ·  2024/08/15 04:06

Moomoo AI 已提取核心信息

Arcutis Biotherapeutics reported strong Q2 2024 financial results with total product revenues reaching $30.9M, comprising $17.3M from ZORYVE cream and $13.6M from ZORYVE foam. Sales grew 547% YoY and 43% QoQ, with improved gross-to-net margins now in the high 50% range. The company achieved sustained prescription growth with a 42% QoQ increase in total U.S. franchise unit demand.The company expanded its market reach through a co-promotion agreement with Kowa Pharmaceuticals America to target primary care and pediatric offices. Additionally, Arcutis submitted an sNDA for ZORYVE foam for scalp and body psoriasis treatment. The company also successfully amended its $200M term loan, securing better terms including a lower interest rate and extended maturity to 2029.Financial position remains solid with $363.1M in cash and equivalents as of June 30, 2024. Q2 net loss was $52.3M ($0.42 per share), improved from $71.0M ($1.16 per share) in Q2 2023. Operating expenses included $19.3M for R&D and $58.2M for SG&A, reflecting continued investment in commercial launches and pipeline development.
Arcutis Biotherapeutics reported strong Q2 2024 financial results with total product revenues reaching $30.9M, comprising $17.3M from ZORYVE cream and $13.6M from ZORYVE foam. Sales grew 547% YoY and 43% QoQ, with improved gross-to-net margins now in the high 50% range. The company achieved sustained prescription growth with a 42% QoQ increase in total U.S. franchise unit demand.The company expanded its market reach through a co-promotion agreement with Kowa Pharmaceuticals America to target primary care and pediatric offices. Additionally, Arcutis submitted an sNDA for ZORYVE foam for scalp and body psoriasis treatment. The company also successfully amended its $200M term loan, securing better terms including a lower interest rate and extended maturity to 2029.Financial position remains solid with $363.1M in cash and equivalents as of June 30, 2024. Q2 net loss was $52.3M ($0.42 per share), improved from $71.0M ($1.16 per share) in Q2 2023. Operating expenses included $19.3M for R&D and $58.2M for SG&A, reflecting continued investment in commercial launches and pipeline development.
Arcutis Biotherapeutics报告了2024年第二季度强劲的财务业绩，总产品收入达到3090万美元，其中ZORYVE乳膏贡献了1730万美元，ZORYVE泡沫贡献了1360万美元。销售同比增长547%，环比增长43%，毛利与净利的比率提高到50%的高位。公司实现了持续的处方增长，美国特许经营单位总需求环比增长42%。公司通过与光和科药品美国公司签署的共同推广协议扩展市场覆盖，目标是初级医疗和儿科诊所。此外，Arcutis提交了ZORYVE泡沫用于头皮和身体银屑病治疗的sNDA。公司还成功修订了20000万美元的定期贷款，确保了更好的条款，包括更低的利率和延长至2029年的到期日...展开全部
Arcutis Biotherapeutics报告了2024年第二季度强劲的财务业绩，总产品收入达到3090万美元，其中ZORYVE乳膏贡献了1730万美元，ZORYVE泡沫贡献了1360万美元。销售同比增长547%，环比增长43%，毛利与净利的比率提高到50%的高位。公司实现了持续的处方增长，美国特许经营单位总需求环比增长42%。公司通过与光和科药品美国公司签署的共同推广协议扩展市场覆盖，目标是初级医疗和儿科诊所。此外，Arcutis提交了ZORYVE泡沫用于头皮和身体银屑病治疗的sNDA。公司还成功修订了20000万美元的定期贷款，确保了更好的条款，包括更低的利率和延长至2029年的到期日。截至2024年6月30日，财务状况依然稳健，现金及等价物为36310万美元。第二季度净亏损为5230万（每股0.42美元），较2023年第二季度的7100万（每股1.16美元）有所改善。营业费用包括1930万用于研发和5820万用于销售、一般和行政，反映了在商业推出和产品线开发上的持续投资。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间